Regulus Therapeutics shares are trading higher after the company announced topline results from the third cohort of patients in its Phase 1b MAD study of RGLS8429 for the treatment of ADPKD.
Portfolio Pulse from Benzinga Newsdesk
Regulus Therapeutics shares are trading higher following the announcement of positive topline results from the third cohort of patients in its Phase 1b MAD study of RGLS8429 for the treatment of ADPKD.
June 24, 2024 | 11:43 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Regulus Therapeutics shares are trading higher after the company announced positive topline results from the third cohort of patients in its Phase 1b MAD study of RGLS8429 for the treatment of ADPKD.
The positive topline results from the Phase 1b MAD study of RGLS8429 indicate potential efficacy in treating ADPKD, which is likely to boost investor confidence and drive the stock price higher in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100